Suki Subbiah

2.6k total citations
12 papers, 50 citations indexed

About

Suki Subbiah is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Suki Subbiah has authored 12 papers receiving a total of 50 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 5 papers in Pathology and Forensic Medicine and 5 papers in Oncology. Recurrent topics in Suki Subbiah's work include Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and Galectins and Cancer Biology (3 papers). Suki Subbiah is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and Galectins and Cancer Biology (3 papers). Suki Subbiah collaborates with scholars based in United States and Mexico. Suki Subbiah's co-authors include Joseph M. Tuscano, Michael Wang, Iris Isufi, Tanya Siddiqi, Catriona Jamieson, Gina G. Chung, Hun Ju Lee, Nicole Lamanna, James B. Breitmeyer and Jean L. Koff and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Suki Subbiah

11 papers receiving 49 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Suki Subbiah United States 5 31 23 21 12 10 12 50
Anna Alperovich United States 4 19 0.6× 16 0.7× 27 1.3× 7 0.6× 7 0.7× 10 42
Nicolas Daguindau France 4 16 0.5× 13 0.6× 14 0.7× 22 1.8× 5 0.5× 14 42
Valentina Bonuomo Italy 4 23 0.7× 8 0.3× 13 0.6× 10 0.8× 10 1.0× 10 50
Hagop M. Kantarjian United States 3 16 0.5× 49 2.1× 22 1.0× 22 1.8× 12 1.2× 5 58
Peter Bruenker Switzerland 3 27 0.9× 22 1.0× 29 1.4× 20 1.7× 18 1.8× 9 61
Matthias Seifert Germany 2 11 0.4× 23 1.0× 26 1.2× 10 0.8× 5 0.5× 4 46
ShaoNing Yang United States 4 23 0.7× 7 0.3× 23 1.1× 16 1.3× 48 4.8× 8 88
Alexandra Christodoulou United States 3 7 0.2× 19 0.8× 19 0.9× 14 1.2× 19 1.9× 6 45
Edoardo Simonetti Italy 4 24 0.8× 42 1.8× 38 1.8× 21 1.8× 19 1.9× 9 65
Neus Ruiz‐Xivillé Spain 6 8 0.3× 15 0.7× 16 0.8× 8 0.7× 10 1.0× 8 34

Countries citing papers authored by Suki Subbiah

Since Specialization
Citations

This map shows the geographic impact of Suki Subbiah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suki Subbiah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suki Subbiah more than expected).

Fields of papers citing papers by Suki Subbiah

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suki Subbiah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suki Subbiah. The network helps show where Suki Subbiah may publish in the future.

Co-authorship network of co-authors of Suki Subbiah

This figure shows the co-authorship network connecting the top 25 collaborators of Suki Subbiah. A scholar is included among the top collaborators of Suki Subbiah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suki Subbiah. Suki Subbiah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Wu, Xiao‐Cheng, Qingzhao Yu, Mei‐Chin Hsieh, et al.. (2023). Effect of chronic disease on racial difference in COVID-19–associated hospitalization among cancer patients. JNCI Journal of the National Cancer Institute. 115(10). 1204–1212.
2.
Subbiah, Suki, Jessica Y. Islam, Cassandra Hennessy, et al.. (2022). COVID-19 outcomes in patients with cancer and HIV: An analysis of the COVID-19 and Cancer Consortium (CCC19).. Journal of Clinical Oncology. 40(16_suppl). e18790–e18790. 1 indexed citations
3.
Lee, Hun Ju, Michael Y. Choi, Tanya Siddiqi, et al.. (2022). Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 40(16_suppl). 7520–7520. 5 indexed citations
4.
Lee, Hun Ju, Michael Y. Choi, Tanya Siddiqi, et al.. (2022). Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Blood. 140(Supplement 1). 566–568. 7 indexed citations
5.
Subbiah, Suki, et al.. (2021). High CD4 count and bone marrow infiltration in untreated hiv-associated Kaposi sarcoma: A case report and literature review. SHILAP Revista de lepidopterología. 3. 100063–100063. 1 indexed citations
6.
Thomas, Katharine, et al.. (2021). Association and prevalence of venous thromboembolism in cancer patients with COVID-19: A single healthcare system experience.. Journal of Clinical Oncology. 39(15_suppl). 2627–2627. 4 indexed citations
7.
Lee, Hun Ju, Michael Y. Choi, Tanya Siddiqi, et al.. (2021). Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL). Blood. 138(Supplement 1). 3534–3534. 1 indexed citations
8.
Lee, Hun Ju, Michael Y. Choi, Tanya Siddiqi, et al.. (2021). Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 39(15_suppl). 7556–7556. 20 indexed citations
9.
Lee, Hun Ju, Michael Y. Choi, Tanya Siddiqi, et al.. (2020). Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study. Blood. 136(Supplement 1). 45–46. 5 indexed citations
10.
Lee, Hun Ju, Michael Y. Choi, Tanya Siddiqi, et al.. (2020). Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 38(15_suppl). 8036–8036. 3 indexed citations
11.
Davies, Terry F., Wilson I. Gonsalves, Tsewang Tashi, et al.. (2011). Long-standing diabetes and its effects on outcomes in colon cancer.. Journal of Clinical Oncology. 29(15_suppl). e14019–e14019. 1 indexed citations
12.
Didwaniya, Neha, Rose Edmonds, Peter T. Silberstein, & Suki Subbiah. (2011). Survival outcomes based on race in gastric carcinoma: A SEER database analysis.. Journal of Clinical Oncology. 29(4_suppl). 5–5. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Alperovich Breakdown of academic impact, for papers by Nicolas Daguindau Breakdown of academic impact, for papers by Valentina Bonuomo Breakdown of academic impact, for papers by Hagop M. Kantarjian Breakdown of academic impact, for papers by Peter Bruenker Breakdown of academic impact, for papers by Matthias Seifert Breakdown of academic impact, for papers by ShaoNing Yang Breakdown of academic impact, for papers by Alexandra Christodoulou Breakdown of academic impact, for papers by Edoardo Simonetti Breakdown of academic impact, for papers by Neus Ruiz‐Xivillé
Rankless by CCL
2026